r.rotation.to⌕ Search stocks, people, sectors
Following this device: dark.
Request a free account

Follow the people · Insider

BC

Bihua Chen

Insider · Director and 10% owner · BLSM

Bihua Chen files insider transactions with the SEC as a director and 10% owner of BlossomHill Therapeutics. We hold 2 disclosed purchases and sales filed since 7 November 2016, 1 of them in the last 90 days.

  • Files for 20 companiesBLSM, BBOT, HLXC, CRBP and 16 more
  • Disclosed buys and sells2 in all, 1 in the last 90 days
  • Last disclosure10 August 2026

Positions held

20 posts we hold — a term names its own dates; a run of filings only says when they filed
  • Filed 6 August 2026 — 10 August 2026Director and 10% owner · BlossomHill Therapeutics 6 Form 4 lines · source: SEC Form 4
  • Filed 11 August 2025 — 1 July 2026Director and 10% owner · BridgeBio Oncology Therapeutics 15 Form 4 lines · source: SEC Form 4
  • Filed 22 January 2026 — 26 January 2026Chairperson and CEO · Helix Acquisition Corp. III 8 Form 4 lines · source: SEC Form 4
  • Filed 26 January 2024 — 11 December 202510% owner · Corbus Pharmaceuticals Holdings 25 Form 4 lines · source: SEC Form 4
  • Filed 14 June 2023 — 11 June 2025Director and 10% owner · Biomea Fusion 2 Form 4 lines · source: SEC Form 4
  • Filed 14 February 2025 — 14 February 2025Other role · Aardvark Therapeutics 3 Form 4 lines · source: SEC Form 4
  • Filed 13 February 2024 — 8 February 2025CEO and Chairperson · Helix Acquisition Corp. II 5 Form 4 lines · source: SEC Form 4
  • Filed 27 September 2024 — 27 September 2024Other role · BioAge Labs 3 Form 4 lines · source: SEC Form 4
  • Filed 20 July 2023 — 20 July 2023Other role · GreenLight Biosciences Holdings, PBC 1 Form 4 line · source: SEC Form 4
  • Filed 5 April 2022 — 30 June 202310% owner · MoonLake Immunotherapeutics 35 Form 4 lines · source: SEC Form 4
  • Filed 26 July 2021 — 22 June 2023Director · Erasca 4 Form 4 lines · source: SEC Form 4
  • Filed 18 April 2023 — 20 April 202310% owner · Ambrx Biopharma 3 Form 4 lines · source: SEC Form 4
  • Filed 25 October 2021 — 25 October 2021Other role · Ventyx Biosciences 4 Form 4 lines · source: SEC Form 4
  • Filed 17 September 2021 — 17 September 2021DirectorOther · Tyra Biosciences 3 Form 4 lines · source: SEC Form 4
  • Filed 29 June 2021 — 29 June 202110% owner · Elevation Oncology 3 Form 4 lines · source: SEC Form 4
  • Filed 27 April 2021 — 27 April 2021Director · Rain Therapeutics 3 Form 4 lines · source: SEC Form 4
  • Filed 18 December 2020 — 18 December 2020Director and 10% owner · BioAtla 3 Form 4 lines · source: SEC Form 4
  • Filed 22 October 2020 — 22 October 2020CEO and Chairman · Helix Acquisition 1 Form 4 line · source: SEC Form 4
  • Filed 30 June 2020 — 30 June 2020Director and 10% owner · Akouos 3 Form 4 lines · source: SEC Form 4
  • Filed 25 June 2018 — 25 June 2018Director and 10% owner · Kezar Life Sciences 5 Form 4 lines · source: SEC Form 4

Every transaction

139 transactions from SEC Form 4 — one row each, sort any column, open a row for the filing
139 of 139 shown
10 Aug 202610 Aug 2026SEC Form 40 dconvertednot a tradeBlossomHill Therapeutics1,599,993 sharesup +37.6%up +37.6%
10 Aug 202610 Aug 2026SEC Form 40 dconvertednot a tradeBlossomHill Therapeutics1,701,541 sharesup +37.6%up +37.6%
10 Aug 202610 Aug 2026SEC Form 40 dbought on the open marketBlossomHill Therapeutics312,500 sharesup +37.6%up +37.6%
10 Aug 202610 Aug 2026SEC Form 40 dconvertednot a tradeBlossomHill Therapeuticsderivative1,599,993 sharesup +37.6%up +37.6%
10 Aug 202610 Aug 2026SEC Form 40 dconvertednot a tradeBlossomHill Therapeuticsderivative1,701,541 sharesup +37.6%up +37.6%
6 Aug 202610 Aug 2026SEC Form 44 dwas grantednot a tradeBlossomHill Therapeuticsderivative23,904 shares—up +37.6%
1 Jul 20266 Jul 2026SEC Form 45 dacquired or disposed of, othernot a tradeBridgeBio Oncology Therapeutics4,528,186 sharesdown −13.4%down −19.7%
1 Jul 20266 Jul 2026SEC Form 45 dacquired or disposed of, othernot a tradeBridgeBio Oncology Therapeutics2,692,459 sharesdown −13.4%down −19.7%
1 Jul 20266 Jul 2026SEC Form 45 dacquired or disposed of, othernot a tradeBridgeBio Oncology Therapeutics1,704,862 sharesdown −13.4%down −19.7%
1 Jul 20266 Jul 2026SEC Form 45 dacquired or disposed of, othernot a tradeBridgeBio Oncology Therapeutics130,865 sharesdown −13.4%down −19.7%
16 Jun 202618 Jun 2026SEC Form 42 dwas grantednot a tradeBridgeBio Oncology Therapeuticsderivative31,675 sharesdown −12.6%down −10.6%
26 Jan 202628 Jan 2026SEC Form 42 dwas grantednot a tradeHelix Acquisition Corp. III497,500 sharesup +5.7%up +5.3%
26 Jan 202628 Jan 2026SEC Form 42 dbought on the open marketHelix Acquisition Corp. III800,000 sharesup +5.7%up +5.3%
26 Jan 202628 Jan 2026SEC Form 42 dwas grantednot a tradeHelix Acquisition Corp. III497,500 sharesup +5.7%up +5.3%
26 Jan 202628 Jan 2026SEC Form 42 dbought on the open marketHelix Acquisition Corp. III800,000 sharesup +5.7%up +5.3%
26 Jan 202626 Jan 2026SEC Form 40 dwas grantednot a tradeHelix Acquisition Corp. III497,500 sharesup +5.7%up +5.7%
22 Jan 202628 Jan 2026SEC Form 46 dacquired or disposed of, othernot a tradeHelix Acquisition Corp. IIIderivative718,750 shares—up +5.3%
22 Jan 202628 Jan 2026SEC Form 46 dacquired or disposed of, othernot a tradeHelix Acquisition Corp. IIIderivative718,750 shares—up +5.3%
22 Jan 202626 Jan 2026SEC Form 44 dacquired or disposed of, othernot a tradeHelix Acquisition Corp. IIIderivative718,750 shares—up +5.7%
11 Dec 202515 Dec 2025SEC Form 44 dsold on the open marketCorbus Pharmaceuticals Holdings30,029 sharesdown −8.5%down −6.5%
11 Aug 202513 Aug 2025SEC Form 42 dreturned to the issuernot a tradeBridgeBio Oncology Therapeuticsderivative307,874 sharesdown −31.8%down −31.0%
11 Aug 202513 Aug 2025SEC Form 42 dexercised options overnot a tradeBridgeBio Oncology Therapeuticsderivative4,172,126 sharesdown −31.8%down −31.0%
11 Aug 202513 Aug 2025SEC Form 42 dexercised options overnot a tradeBridgeBio Oncology Therapeutics4,172,126 sharesdown −31.8%down −31.0%
11 Aug 202513 Aug 2025SEC Form 42 dreturned to the issuernot a tradeBridgeBio Oncology Therapeutics152,940 sharesdown −31.8%down −31.0%
11 Aug 202513 Aug 2025SEC Form 42 dwas grantednot a tradeBridgeBio Oncology Therapeutics760,496 sharesdown −31.8%down −31.0%
11 Aug 202513 Aug 2025SEC Form 42 dwas grantednot a tradeBridgeBio Oncology Therapeutics639,110 sharesdown −31.8%down −31.0%
11 Aug 202513 Aug 2025SEC Form 42 dwas grantednot a tradeBridgeBio Oncology Therapeutics5,598,425 sharesdown −31.8%down −31.0%
11 Aug 202513 Aug 2025SEC Form 42 dwas grantednot a tradeBridgeBio Oncology Therapeutics1,905,046 sharesdown −31.8%down −31.0%
11 Aug 202513 Aug 2025SEC Form 42 dwas grantednot a tradeBridgeBio Oncology Therapeutics1,762,760 sharesdown −31.8%down −31.0%
11 Aug 202513 Aug 2025SEC Form 42 dwas grantednot a tradeBridgeBio Oncology Therapeutics284,571 sharesdown −31.8%down −31.0%
11 Jun 202513 Jun 2025SEC Form 42 dwas grantednot a tradeBiomea Fusionderivative91,970 sharesdown −26.2%down −21.8%
14 Feb 202519 Feb 2025SEC Form 45 dconvertednot a tradeAardvark Therapeuticsderivative6,780,810 sharesdown −63.0%down −67.0%
14 Feb 202519 Feb 2025SEC Form 45 dconvertednot a tradeAardvark Therapeutics800,189 sharesdown −63.0%down −67.0%
14 Feb 202519 Feb 2025SEC Form 45 dbought on the open marketAardvark Therapeutics187,500 sharesdown −63.0%down −67.0%
8 Feb 202510 Feb 2025SEC Form 42 dacquired or disposed of, othernot a tradeHLXBHelix Acquisition Corp. IIderivative30,000 shares——
27 Sep 20241 Oct 2024SEC Form 44 dconvertednot a tradeBioAge Labsderivative5,263,772 sharesdown −52.0%down −50.2%
27 Sep 20241 Oct 2024SEC Form 44 dconvertednot a tradeBioAge Labs1,179,529 sharesdown −52.0%down −50.2%
27 Sep 20241 Oct 2024SEC Form 44 dbought on the open marketBioAge Labs450,000 sharesdown −52.0%down −50.2%
8 Mar 202411 Mar 2024SEC Form 43 dbought on the open marketCorbus Pharmaceuticals Holdings29,342 sharesdown −80.3%down −76.9%
8 Mar 202411 Mar 2024SEC Form 43 dbought on the open marketCorbus Pharmaceuticals Holdings24,983 sharesdown −80.3%down −76.9%
8 Mar 202411 Mar 2024SEC Form 43 dbought on the open marketCorbus Pharmaceuticals Holdings18,548 sharesdown −80.3%down −76.9%
8 Mar 202411 Mar 2024SEC Form 43 dbought on the open marketCorbus Pharmaceuticals Holdings61,668 sharesdown −80.3%down −76.9%
8 Mar 202411 Mar 2024SEC Form 43 dbought on the open marketCorbus Pharmaceuticals Holdings156,597 sharesdown −80.3%down −76.9%
8 Mar 202411 Mar 2024SEC Form 43 dbought on the open marketCorbus Pharmaceuticals Holdings8,862 sharesdown −80.3%down −76.9%
7 Mar 202411 Mar 2024SEC Form 44 dbought on the open marketCorbus Pharmaceuticals Holdings46,799 sharesdown −78.0%down −76.9%
7 Mar 202411 Mar 2024SEC Form 44 dbought on the open marketCorbus Pharmaceuticals Holdings10,736 sharesdown −78.0%down −76.9%
7 Mar 202411 Mar 2024SEC Form 44 dbought on the open marketCorbus Pharmaceuticals Holdings90,325 sharesdown −78.0%down −76.9%
7 Mar 202411 Mar 2024SEC Form 44 dbought on the open marketCorbus Pharmaceuticals Holdings102,140 sharesdown −78.0%down −76.9%
13 Feb 202413 Feb 2024SEC Form 40 dwas grantednot a tradeHLXBHelix Acquisition Corp. II509,000 shares——
13 Feb 202413 Feb 2024SEC Form 40 dbought on the open marketHLXBHelix Acquisition Corp. II69,360 shares——
13 Feb 202413 Feb 2024SEC Form 40 dbought on the open marketHLXBHelix Acquisition Corp. II1,427,040 shares——
13 Feb 202413 Feb 2024SEC Form 40 dbought on the open marketHLXBHelix Acquisition Corp. II903,600 shares——
26 Jan 202430 Jan 2024SEC Form 44 dbought on the open marketCorbus Pharmaceuticals Holdings14,388 sharesdown −70.0%down −64.8%
26 Jan 202430 Jan 2024SEC Form 44 dbought on the open marketCorbus Pharmaceuticals Holdings15,243 sharesdown −70.0%down −64.8%
26 Jan 202430 Jan 2024SEC Form 44 dbought on the open marketCorbus Pharmaceuticals Holdings36,747 sharesdown −70.0%down −64.8%
26 Jan 202430 Jan 2024SEC Form 44 dbought on the open marketCorbus Pharmaceuticals Holdings31,028 sharesdown −70.0%down −64.8%
26 Jan 202430 Jan 2024SEC Form 44 dbought on the open marketCorbus Pharmaceuticals Holdings29,244 sharesdown −70.0%down −64.8%
26 Jan 202430 Jan 2024SEC Form 44 dbought on the open marketCorbus Pharmaceuticals Holdings2,654 sharesdown −70.0%down −64.8%
26 Jan 202430 Jan 2024SEC Form 44 dbought on the open marketCorbus Pharmaceuticals Holdings4,125 sharesdown −70.0%down −64.8%
26 Jan 202430 Jan 2024SEC Form 44 dbought on the open marketCorbus Pharmaceuticals Holdings3,866 sharesdown −70.0%down −64.8%
26 Jan 202430 Jan 2024SEC Form 44 dbought on the open marketCorbus Pharmaceuticals Holdings18,055 sharesdown −70.0%down −64.8%
26 Jan 202430 Jan 2024SEC Form 44 dbought on the open marketCorbus Pharmaceuticals Holdings31,549 sharesdown −70.0%down −64.8%
26 Jan 202430 Jan 2024SEC Form 44 dbought on the open marketCorbus Pharmaceuticals Holdings32,295 sharesdown −70.0%down −64.8%
26 Jan 202430 Jan 2024SEC Form 44 dbought on the open marketCorbus Pharmaceuticals Holdings16,484 sharesdown −70.0%down −64.8%
26 Jan 202430 Jan 2024SEC Form 44 dbought on the open marketCorbus Pharmaceuticals Holdings43,754 sharesdown −70.0%down −64.8%
26 Jan 202430 Jan 2024SEC Form 44 dbought on the open marketCorbus Pharmaceuticals Holdings3,200 sharesdown −70.0%down −64.8%
20 Jul 202324 Jul 2023SEC Form 44 dsold on the open marketGRNAGreenLight Biosciences Holdings, PBC9,188,659 shares——
30 Jun 20235 Jul 2023SEC Form 45 dbought on the open marketMoonLake Immunotherapeutics800,000 sharesdown −73.1%down −73.7%
26 Jun 202328 Jun 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics1,481 sharesdown −70.1%down −73.0%
26 Jun 202328 Jun 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics3,755 sharesdown −70.1%down −73.0%
26 Jun 202328 Jun 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics10,593 sharesdown −70.1%down −73.0%
26 Jun 202328 Jun 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics38,623 sharesdown −70.1%down −73.0%
26 Jun 202328 Jun 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics50,642 sharesdown −70.1%down −73.0%
26 Jun 202328 Jun 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics61,042 sharesdown −70.1%down −73.0%
26 Jun 202328 Jun 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics66,087 sharesdown −70.1%down −73.0%
26 Jun 202328 Jun 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics31,558 sharesdown −70.1%down −73.0%
26 Jun 202328 Jun 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics10,946 sharesdown −70.1%down −73.0%
26 Jun 202328 Jun 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics37,783 sharesdown −70.1%down −73.0%
26 Jun 202328 Jun 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics59,787 sharesdown −70.1%down −73.0%
26 Jun 202328 Jun 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics17,662 sharesdown −70.1%down −73.0%
26 Jun 202328 Jun 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics8,697 sharesdown −70.1%down −73.0%
26 Jun 202328 Jun 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics4,725 sharesdown −70.1%down −73.0%
26 Jun 202328 Jun 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics21,823 sharesdown −70.1%down −73.0%
26 Jun 202328 Jun 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics18,949 sharesdown −70.1%down −73.0%
26 Jun 202328 Jun 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics1,453 sharesdown −70.1%down −73.0%
26 Jun 202328 Jun 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics1,894 sharesdown −70.1%down −73.0%
26 Jun 202328 Jun 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics295 sharesdown −70.1%down −73.0%
26 Jun 202328 Jun 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics1,302 sharesdown −70.1%down −73.0%
26 Jun 202328 Jun 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics417 sharesdown −70.1%down −73.0%
26 Jun 202328 Jun 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics136 sharesdown −70.1%down −73.0%
26 Jun 202328 Jun 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics139 sharesdown −70.1%down −73.0%
26 Jun 202328 Jun 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics95 sharesdown −70.1%down −73.0%
26 Jun 202328 Jun 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics16 sharesdown −70.1%down −73.0%
26 Jun 202328 Jun 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics15 sharesdown −70.1%down −73.0%
26 Jun 202328 Jun 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics85 sharesdown −70.1%down −73.0%
22 Jun 202326 Jun 2023SEC Form 44 dwas grantednot a tradeErascaderivative60,000 sharesup +490.2%up +475.1%
14 Jun 202316 Jun 2023SEC Form 42 dwas grantednot a tradeBiomea Fusionderivative6,989 sharesdown −95.3%down −94.7%
20 Apr 202320 Apr 2023SEC Form 40 dbought on the open marketAMAMAmbrx Biopharma886,634 shares——
19 Apr 202320 Apr 2023SEC Form 41 dbought on the open marketAMAMAmbrx Biopharma951,909 shares——
18 Apr 202320 Apr 2023SEC Form 42 dbought on the open marketAMAMAmbrx Biopharma3,376,646 shares——
21 Mar 202322 Mar 2023SEC Form 41 dbought on the open marketMoonLake Immunotherapeutics238,511 sharesdown −37.7%down −35.4%
20 Mar 202322 Mar 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics446,881 sharesdown −35.6%down −35.4%
20 Mar 202322 Mar 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics63,700 sharesdown −35.6%down −35.4%
20 Mar 202322 Mar 2023SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics78,008 sharesdown −35.6%down −35.4%
22 Jun 202224 Jun 2022SEC Form 42 dwas grantednot a tradeErascaderivative40,000 sharesup +193.5%up +164.8%
5 Apr 20227 Apr 2022SEC Form 42 dconvertednot a tradeMoonLake Immunotherapeuticsderivative2,785,000 sharesup +3.5%up +6.5%
5 Apr 20227 Apr 2022SEC Form 42 dconvertednot a tradeMoonLake Immunotherapeutics2,785,000 sharesup +3.5%up +6.5%
5 Apr 20227 Apr 2022SEC Form 42 dbought on the open marketMoonLake Immunotherapeutics2,850,000 sharesup +3.5%up +6.5%
25 Oct 202127 Oct 2021SEC Form 42 dconvertednot a tradeVTYXVentyx Biosciencesderivative548,288 shares——
25 Oct 202127 Oct 2021SEC Form 42 dconvertednot a tradeVTYXVentyx Biosciencesderivative237,015 shares——
25 Oct 202127 Oct 2021SEC Form 42 dconvertednot a tradeVTYXVentyx Biosciences785,303 shares——
25 Oct 202127 Oct 2021SEC Form 42 dbought on the open marketVTYXVentyx Biosciences625,000 shares——
17 Sep 202121 Sep 2021SEC Form 44 dconvertednot a tradeTyra Biosciencesderivative757,432 sharesup +10.5%up +11.0%
17 Sep 202121 Sep 2021SEC Form 44 dconvertednot a tradeTyra Biosciences757,432 sharesup +10.5%up +11.0%
17 Sep 202121 Sep 2021SEC Form 44 dbought on the open marketTyra Biosciences312,500 sharesup +10.5%up +11.0%
10 Aug 202110 Aug 2021SEC Form 40 dbought on the open marketErasca200,000 sharesdown −22.5%down −22.5%
26 Jul 202110 Aug 2021SEC Form 415 dsold on the open marketErasca200,000 sharesdown −16.7%down −22.5%
29 Jun 20211 Jul 2021SEC Form 42 dconvertednot a tradeELEVElevation Oncologyderivative1,983,168 shares——
29 Jun 20211 Jul 2021SEC Form 42 dconvertednot a tradeELEVElevation Oncology1,983,168 shares——
29 Jun 20211 Jul 2021SEC Form 42 dbought on the open marketELEVElevation Oncology250,000 shares——
27 Apr 202129 Apr 2021SEC Form 42 dconvertednot a tradeRain Therapeuticsderivative2,512,561 shares——
27 Apr 202129 Apr 2021SEC Form 42 dconvertednot a tradeRain Therapeutics2,326,657 shares——
27 Apr 202129 Apr 2021SEC Form 42 dbought on the open marketRain Therapeutics450,000 shares——
18 Dec 202022 Dec 2020SEC Form 44 dconvertednot a tradeBCABBioAtladerivative1,492,060 sharesdown −99.9%down −99.9%
18 Dec 202022 Dec 2020SEC Form 44 dconvertednot a tradeBCABBioAtla1,492,060 sharesdown −99.9%down −99.9%
18 Dec 202022 Dec 2020SEC Form 44 dbought on the open marketBCABBioAtla800,000 sharesdown −99.9%down −99.9%
22 Oct 202022 Oct 2020SEC Form 40 dbought on the open marketHLXAHelix Acquisition430,000 shares——
30 Jun 20202 Jul 2020SEC Form 42 dconvertednot a tradeAKUSAkouosderivative499,989 shares——
30 Jun 20202 Jul 2020SEC Form 42 dconvertednot a tradeAKUSAkouos499,989 shares——
30 Jun 20202 Jul 2020SEC Form 42 dbought on the open marketAKUSAkouos290,000 shares——
25 Jun 201827 Jun 2018SEC Form 42 dconvertednot a tradeKZRKezar Life Sciencesderivative315,488 shares——
25 Jun 201827 Jun 2018SEC Form 42 dconvertednot a tradeKZRKezar Life Sciencesderivative1,007,421 shares——
25 Jun 201827 Jun 2018SEC Form 42 dconvertednot a tradeKZRKezar Life Sciences315,488 shares——
25 Jun 201827 Jun 2018SEC Form 42 dconvertednot a tradeKZRKezar Life Sciences1,007,421 shares——
25 Jun 201827 Jun 2018SEC Form 42 dbought on the open marketKZRKezar Life Sciences250,000 shares——
7 Nov 20167 Nov 2016SEC Form 40 dbought on the open marketPTIProteostasis Therapeutics231,700 shares——
4 Nov 20167 Nov 2016SEC Form 43 dbought on the open marketPTIProteostasis Therapeutics2,597 shares——
4 Nov 20167 Nov 2016SEC Form 43 dbought on the open marketPTIProteostasis Therapeutics73,403 shares——
3 Nov 20167 Nov 2016SEC Form 44 dbought on the open marketPTIProteostasis Therapeutics20,277 shares——

Both percentages are the stock’s move, not Bihua Chen’s return: a disclosure gives a band, never an amount, so nobody can say how much was bought or what it made. They run to the last close we hold — 9 Sep 2026, except where a name has since delisted, when the row names its own last session. We publish no close, no volume and no dollar figure behind them. 103 of the 139 rows shown carry a percentage; the rest are dashes with the reason on the row.

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.

Some filings reach us as photographs of paper rather than as a form we can read as text. Those are shown here only once they have been read and checked, so this page can hold fewer lines than the filings behind it contain. The link on every row opens the original document, which is always the full record.